What type of study is this?

This is a Cohort Study study (also classified as: Animal Study, Quantitative Study, Experimental Study).

Tussilagone suppresses triple-negative breast cancer progression by inhibiting the TLR4/NF-κB pathway and enhancing anti-tumor immunity

View Full Paper

Ask AI

Bookmark

Authors

Experimental analysis reveals that tussilagone decreases tumor progression in triple-negative breast cancer, indicating enhanced anti-tumor immunity.

Tussilagone significantly inhibits triple-negative breast cancer cell proliferation and invasion.
Key evidence shows a dose-dependent reduction in TNBC progression, correlating with TLR4/NF-κB pathway suppression.
Assessment utilized cell viability, invasion assays, and co-culture studies to evaluate immune response.
Findings highlight tussilagone's promise as a therapeutic candidate in triple-negative breast cancer.

Huang et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

View Full Paper

Ask AI

Bookmark

Authors

Experimental analysis reveals that tussilagone decreases tumor progression in triple-negative breast cancer, indicating enhanced anti-tumor immunity.

Tussilagone significantly inhibits triple-negative breast cancer cell proliferation and invasion.
Key evidence shows a dose-dependent reduction in TNBC progression, correlating with TLR4/NF-κB pathway suppression.
Assessment utilized cell viability, invasion assays, and co-culture studies to evaluate immune response.
Findings highlight tussilagone's promise as a therapeutic candidate in triple-negative breast cancer.

Huang et al. (2025) studied this question.

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark